Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $91 | $88 | $67 | $29 |
| G&A Expenses | $0 | $30 | $23 | $7 |
| SG&A Expenses | $27 | $30 | $23 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $118 | $119 | $90 | $36 |
| Operating Income | -$119 | -$119 | -$90 | -$36 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $2 | $0 | $0 |
| Pre-Tax Income | -$113 | -$116 | -$90 | -$36 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$113 | -$114 | -$89 | -$35 |
| % Margin | – | – | – | – |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 |
| % Growth | 6.6% | -26.3% | -153.1% | – |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 |
| Weighted Avg Shares Out | 47 | 44 | 44 | 43 |
| Weighted Avg Shares Out Dil | 47 | 44 | 44 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$118 | -$118 | -$90 | -$36 |
| % Margin | – | – | – | – |